Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
La Revue Du Praticien|July 17, 2023
[Toxicity of targeted therapies and immunotherapy with checkpointinhibitors in Hodgkin lymphoma]Jean-Marie Michot, Julien Lazarovici
Expert Review of Anticancer Therapy|July 8, 2021
Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacyVincent Camus, Camille Bigenwald, Vincent Ribrag, et al.
Ear, Nose, & Throat Journal|July 7, 2022
Orofacial intramuscular lymphoma: first presentationLucas T Duong, Marie Rollin, François Bidault, et al.
Human Vaccines & Immunotherapeutics|June 8, 2021
Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?Selma Addou, Clémentine Sarkozy, Julien Lazarovici, et al.
European Journal of Cancer (Oxford, England : 1990)|September 12, 2017
Challenges and perspectives in the immunotherapy of Hodgkin lymphomaJean-Marie Michot, Julien Lazarovici, David Ghez, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 5, 2020
Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin LymphomaLayal El Halabi, Julien Adam, Pauline Gravelle, et al.
Bulletin Du Cancer|June 1, 2016
[Consortium for detection and management of lung damage induced by bleomycin]Josette Biya, Annabelle Stoclin, Sandra Dury, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 5, 2020
Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy ExperienceElie Rassy, Alina Danu, Toni Ibrahim, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 10, 2017
<sup>18</sup>F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint InhibitorLaurent Dercle, Romain-David Seban, Julien Lazarovici, et al.
Cancers|March 11, 2023
Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 StudyFabio Andreozzi, Matteo Dragani, Cyril Quivoron, et al.
Pageof 5